In a small phase II study, alectinib has shown activity in melanoma, papillary urothelial carcinoma and colon adenocarcinoma with ALK rearrangements, but not in any cases of solid organ tumours with ALK mutations or amplification [8]. Here, ALK is linked to melanoma.